Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of dupilumab in Japanese patients with moderate-to-severe asthma after TRAVERSE-LTS12551
jRCT2080224030Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of dupilumab in asthma, sponsored by Sanofi. Primary endpoint: Long-term safety and tolerability of dupilumab. Started Aug 2018; status: completed.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2080224030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224030.